NEW YORK (TheStreet) -- RATINGS CHANGES
Amsurg (AMSG) was upgraded at Robert Baird to outperform from neutral. Twelve-month price target is $55. Company is expanding its addressable market and can deliver higher organic growth, Robert Baird said.
[Read: United Should Close Dulles Hub]
Editor's note: To see analysts' stock comments and changes to price targets and earnings estimates, go to "Street Notes" which is available only to Real Money subscribers. To find out how to become a subscriber, please click here.
This article was written by a staff member of TheStreet.